Active metabolomics identify potential functional metabolites for preeclampsia prevention

Area of Science:

• Metabolomics
• Biochemistry
• Obstetrics

Background:

• Preeclampsia (PE) is a major cause of maternal and fetal mortality.
• Limited effective treatments exist for PE.
• Metabolomics can identify biomarkers and therapeutic targets for PE.

Purpose of the Study:

• To compare serum metabolomics profiles in preeclampsia and normal pregnancies.
• To investigate the role of LysoPE(16:0) in trophoblast function.
• To explore the molecular mechanisms underlying LysoPE(16:0)'s effects.

Main Methods:

• Untargeted liquid chromatography-mass spectrometry (LC-MS) metabolomics.
• Analysis of serum samples from PE patients and controls.
• Functional assays on trophoblast cells and mechanistic studies involving GSK-3β.

Main Results:

• Significant alterations in lysophosphatidylcholines and organic acids were observed.
• LysoPE(16:0) was downregulated in PE serum.
• LysoPE(16:0) promoted trophoblast cell invasion and migration, potentially via GSK-3β/β-Catenin pathway modulation.

Conclusions:

• LysoPE(16:0) plays a role in PE pathophysiology.
• LysoPE(16:0) may be a therapeutic target or biomarker for PE.
• Modulation of the GSK-3β/β-Catenin pathway by LysoPE(16:0) offers new insights into PE treatment.